Supplementary Table 1. Baseline characteristics of included and excluded patients

Characteristics	Total (n=6,412)	Exclude (n=511)	Include (n=5,901)	P
Age (yr)	64.8 (57.0–71.4)	64.8 (57.0–72.5)	64.8 (56.9–71.3)	0.282
Female sex	2,170 (33.8)	191 (37.4)	1,979 (33.5)	0.078
Han ethnicity	6,282 (98.0)	498 (97.5)	5,784 (98.0)	0.388
BMI (kg/m^2)	24.5 (22.6–26.6)	24.2 (22.5–26.1)	24.5 (22.6–26.6)	0.145
Medical history				
Hypertension	4,730 (73.8)	373 (73.0)	4,357 (73.8)	0.678
Diabetes mellitus	2,042 (31.9)	165 (32.3)	1,877 (31.8)	0.823
Dyslipidemia	1,783 (27.8)	91 (17.8)	1,692 (28.7)	<0.001
Previous ischemic stroke	1,350 (21.1)	89 (17.4)	1,261 (21.4)	0.035
Previous TIA	88 (1.4)	8 (1.6)	80 (1.4)	0.696
Myocardial infarction	96 (1.5)	12 (2.4)	84 (1.4)	0.099
Current smoking	1,981 (30.9)	131 (25.6)	1,850 (31.4)	0.007
CYP2C19 LOF allele carriers				0.776
Intermediate metabolizers	5,001 (78.0)	396 (77.5)	4,605 (78.0)	
Poor metabolizers	1,411 (22.0)	115 (22.5)	1,296 (22.0)	
Time to randomization (h)	14.0 (8.9–20.5)	13.1 (8.5–20.3)	14.0 (9.0–20.5)	0.203
Qualifying event				0.913
Ischemic stroke	5,158 (80.4)	412 (80.6)	4,746 (80.4)	
TIA	1,254 (19.6)	99 (19.4)	1,155 (19.6)	
NIHSS score in patients with qualifying ischemic stroke*	2 (1–3)	2 (1–3)	2 (1–3)	0.914
ABCD^2 score in patients with qualifying TIA[†]	4 (4–5)	5 (4–5)	4 (4–5)	0.680
Previous antiplatelet therapy[‡]	748 (11.7)	60 (11.7)	688 (11.7)	0.956
Previous lipid-lowering therapy[‡]	499 (7.8)	43 (8.4)	456 (7.7)	0.578
Symptomatic intracranial-artery stenosis	1,639 (27.7)	100 (22.4)	1,539 (28.1)	0.009
Symptomatic extracranial-artery stenosis	271 (4.6)	16 (3.6)	255 (4.7)	0.294

Values are presented as median (interquartile range) or n (%).

BMI, body mass index; TIA, transient ischemic attack; LOF, loss-of-function; NIHSS, National Institutes of Health Stroke Scale.

*NIHSS scores range from 0–42, with higher scores indicating more severe stroke; [†]The ABCD^2 score assesses the risk of stroke on the basis of age, blood pressure, clinical features, duration of TIA, and presence or absence of diabetes mellitus, with scores ranging from 0 to 7 and higher scores indicating greater risk; [‡]Medication within 1 month before symptom onset.